Axsome Therapeutics (AXSM) Enterprise Value (2022 - 2025)
Axsome Therapeutics (AXSM) has disclosed Enterprise Value for 4 consecutive years, with -$322.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 2.39% to -$322.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$322.9 million through Dec 2025, down 2.39% year-over-year, with the annual reading at -$322.9 million for FY2025, 2.39% down from the prior year.
- Enterprise Value hit -$322.9 million in Q4 2025 for Axsome Therapeutics, up from -$325.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$73.4 million in Q2 2022 to a low of -$437.1 million in Q2 2023.
- Historically, Enterprise Value has averaged -$288.4 million across 4 years, with a median of -$315.5 million in 2024.
- Biggest five-year swings in Enterprise Value: plummeted 495.57% in 2023 and later rose 27.79% in 2024.
- Year by year, Enterprise Value stood at -$200.8 million in 2022, then plummeted by 92.29% to -$386.2 million in 2023, then grew by 18.34% to -$315.4 million in 2024, then fell by 2.39% to -$322.9 million in 2025.
- Business Quant data shows Enterprise Value for AXSM at -$322.9 million in Q4 2025, -$325.3 million in Q3 2025, and -$303.0 million in Q2 2025.